📇 Rhumatologue ·

M BERNARD DAY

Pourquoi vous devez consulter ce praticien

2 raisons identifiées

Auteur de référence en rhumatologie
50 articles scientifiques publiés — un praticien à la pointe de la recherche
Référence presse grand public
Cité 4 fois dans les médias — pédagogie reconnue

Rhumatologue

RPPS 10001984458

✨ Génération du profil synthétique IA en cours…

Lieu de consultation

Tarifs & secteur de conventionnement

Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).

📊 Comprendre le remboursement

Prendre rendez-vous & contact

🗓 Trouver sur Doctolib 📇 Ajouter à mes contacts

Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.

Top publications · les plus citées

Reported Early Clinical Outcomes of Forward-Planned Multileaf Collimator-Based 3-Dimensional Conformal Spatially Fractionated Radiation Therapy Technique for Large and Bulky Tumors

International journal of radiation oncology, biology, physics · 2025

📚 5 citations🎯 RCR 2.55

Association of hypoperfusion intensity ratio and cerebral blood volume Index with good outcome in patients transferred for thrombectomy

Interventional neuroradiology : journal of peritherapeutic neuroradiology, surgical procedures and related neurosciences · 2025

📚 4 citations🔓 Open Access

Lire l'abstract Crossref ↓

Background Hypoperfusion intensity ratio (HIR) and cerebral blood volume index (CBVI) have been shown to predict clinical outcome, but further validation is needed in patients initially presenting to non-thrombectomy centers. Methods We conducted a retrospective study of patients with an anterior circulation large vessel occlusion (ACLVO) who underwent computed tomography perfusion (CTP) scanning at a non-thrombectomy center and were transferred for consideration of thrombectomy. We evaluated the association of three measures of collateral status (HIR, CBVI, and a collateral score combining both measures) to 90-day modified Rankin scale (mRS). Results We identified 497 eligible patients, of whom 93% underwent thrombectomy. After adjusting for covariates, ascending numerical CBVI was associated with 90-day mRS ≤ 2 in both overall patients and the recanalized subgroup ( n = 436). In the recanalized subgroup, 90-day mRS ≤ 2 among patients with CBVI > 0.7 was 56% versus 36% with CBVI ≤ 0.7 [adjusted OR: 1.73 (1.13–2.65), p = 0.012]. Neither HIR thresholds below 0.4, 0.5, and 0.6, nor a good versus poor collateral score, were associated with independent or improved functional outcome,. Conclusion In this study of ACLVO patients transferred for thrombectomy consideration, ascending numeric CBVI was associated with independent function in both the overall population and the recanalized subgroup, and CBVI > 0.7 was associated with both independent and improved functional outcome in recanalized patients. Among CTP measures of collateral status, CBVI alone may play an important role in stroke prognostication and management for ACLVO patients who initially present to a non-thrombectomy center.

Interim PET after 4 cycles predicts outcome in histomolecularly confirmed primary mediastinal B-cell lymphoma

Blood advances · 2025

📚 4 citations🩺 Clinique🔓 Open Access

Lire l'abstract Crossref ↓

Abstract The GAINED study was a randomized phase 3 trial comparing obinutuzumab (G) with rituximab (R) plus ACVBP (doxorubicin, cyclophosphamide, and prednisone, combined with either vindesine or bleomycin) or CHOP14 (cyclophosphamide, doxorubicin, vincristine, and prednisone, administered on a 14-day schedule) induction, followed by positron emission tomography (PET)–guided consolidation. This post hoc analysis aimed to detail the outcomes of patients with primary mediastinal B-cell lymphoma (PMBL), verified through expert pathological review and the use of gene expression profiling (GEP) and next-generation sequencing. Of 620 centrally reviewed patients, 138 (22.3%) confirmed PMBL cases were analyzed. Baseline characteristics included a median age of 33.5 years, 63.8% female, 55.1% stage III to IV, 90.6% elevated lactate dehydrogenase, 87.6% Eastern Cooperative Oncology Group performance status score of 0 to 1, 62.3% extranodal involvement, 52.6% age-adjusted International Prognostic Index (aaIPI) of 2% to 3%, and 53.6% bulk (&gt;10 cm). Induction regimens were R/G-CHOP14 (56.9%) and R/G-ACVBP (43.1%). Postinduction treatments, based on interim PET results, included: standard consolidation chemotherapy (59.8%) if change in maximum standardized uptake value (ΔSUVmax) of &gt;66% after cycle 2 and &gt;70% after cycle 4 (PET2−/4−), intensive treatment and autologous transplantation (26.8%) if PET2+/4−, and salvage therapy (13.4%) if PET4+ (ΔSUVmax of ≤70%). Among patients with GEP data (n = 107), 38 (35.5%) were PDL1high/PDL2high. Key somatic mutations data (n = 87) included SOCS1 (70.1%), B2M (56.3%), STAT6 (49.4%), TNFAIP3 (47.1%), GNA13 (39.1%), CIITA (37.9%), CD58 (36.8%), and TP53 (29.9%). After a median follow-up of 39.5 months, 2-year progression-free survival (PFS) and overall survival (OS) rates were 86.2% and 93.2%, respectively. In a multivariate model including bulk, aaIPI, and ΔSUVmax PET2/PET4, only bulk and ΔSUVmax PET4 of ≤70% were associated with shorter PFS (hazard ratio, 4.39 [95% confidence interval (CI), 1.28-15.11] and 4.95 [95% CI, 1.71-14.3], respectively), whereas none were associated with OS. The ΔSUVmax-based interim PET4 response emerged as the strongest predictor of patient outcomes in this selected clinical trial population. This trial was registered at www.ClinicalTrials.gov as #NCT01659099.

Cookies & analyse de trafic

M BERNARD DAY

Pourquoi vous devez consulter ce praticien

Lieu de consultation

Tarifs & secteur de conventionnement

Prendre rendez-vous & contact

Articles de presse (4)

Top publications · les plus citées

Publications scientifiques (50) — classées par pathologie

Transversal32

Gériatrie3

Pédiatrie3

Épidémiologie & registres2

Essai clinique2

IA en rhumatologie2

Microbiote2

Vraie vie / RWE2

AINS1

Qualité de vie / PROMs1

Santé mentale / fatigue1

Partager cette fiche